{"id":5980,"date":"2024-09-25T07:34:00","date_gmt":"2024-09-25T05:34:00","guid":{"rendered":"https:\/\/www.ehc.eu\/uncategorized-hr\/azuriranje-o-odstupanju-u-proizvodnji-novo-nordiska-za-novoseven-sto-je-rezultiralo-nestasicama-za-novoeight-i-esperoct\/"},"modified":"2026-04-02T16:31:01","modified_gmt":"2026-04-02T14:31:01","slug":"azuriranje-o-odstupanju-u-proizvodnji-novo-nordiska-za-novoseven-sto-je-rezultiralo-nestasicama-za-novoeight-i-esperoct","status":"publish","type":"post","link":"https:\/\/www.ehc.eu\/hr\/uncategorized-hr\/azuriranje-o-odstupanju-u-proizvodnji-novo-nordiska-za-novoseven-sto-je-rezultiralo-nestasicama-za-novoeight-i-esperoct\/","title":{"rendered":"A\u017euriranje o odstupanju u proizvodnji Novo Nordiska za NovoSeven,\u00a9 \u0161to je rezultiralo nesta\u0161icama za NovoEight\u00a9 i Esperoct\u00a9"},"content":{"rendered":"<!-- hero -->\t<section   class=\"subpage-hero bg-white\">\n\t\t<div class=\"container\">\n\t\t\t<div class=\"relative z-10\">\n\t\t\t\t<div class=\"pt-16 lg:pt-24 pb-24 lg:pb-32\">\n\t\t\t\t\t<div class=\"row justify-between gap-10 lg:gap-0 mt-10 text-center lg:text-left\">\n\t\t\t\t\t\t<div class=\"w-full lg:w-7\/12 lg:self-center\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"title h3\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t\t<p class=\"text-[115%]\">A\u017euriranje o odstupanju u proizvodnji Novo Nordiska za NovoSeven,\u00a9 \u0161to je rezultiralo nesta\u0161icama za NovoEight\u00a9 i Esperoct\u00a9<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<figure class=\"absolute size-[41.8rem] lg:size-[82.8rem] bottom-[-10%] right-[-10rem] lg:right-[-5%] image-contain opacity-100 skip-lazy\" data-parallax>\n\t\t\t\t\t<img decoding=\"async\" loading=\"eager\" src=\"https:\/\/etngbd86n6b.exactdn.com\/wp-content\/themes\/cbd\/img\/content-logo-colorfull-2.svg\" alt=\"content-logo-colorfull\">\n\t\t\t\t<\/figure>\n\t\t\t\t\t\t<\/section>\n<!-- overview -->\t<section   class=\"s-overlay-img s-padding bg-red\">\n\t\t<div class=\"container\">\n\t\t\t<div class=\"row w-full lg:flex-row justify-between text-center lg:text-left gap-14 lg:gap-0 relative z-10\">\n\t\t\t\t\t\t\t\t<div class=\"w-full lg:py-10\">\n\t\t\t\t\t<div class=\"bg-white min-h-full py-12 px-10 lg:py-24 lg:pl-24 xl:pl-44 relative radius-20 z-10\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"content mt-8\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t<p>Sredinom lipnja 2024. <strong>Europski konzorcij za hemofiliju (EHC),<\/strong> <a href=\"https:\/\/www.bleeding.org\/\" target=\"_blank\" rel=\"noopener\"><strong>Nacionalna zaklada za poreme\u0107aje zgru\u0161avanja (NBDF)<\/strong><\/a> i <a href=\"https:\/\/wfh.org\/\" target=\"_blank\" rel=\"noopener\"><strong>Svjetska federacija hemofilije (WFH)<\/strong><\/a> obavije\u0161teni su o odstupanju u proizvodnim linijama nekoliko proizvoda za lije\u010denje hemofilije i drugih koagulopatija koje proizvodi Novo Nordisk u Danskoj. Ovo odstupanje u proizvodnji rezultiralo je time da su neke bo\u010dice NovoSeven (1 i 2 mg) potencijalno bile nedovoljno napunjene u upu\u0107enim zemljama te je rezultiralo nesta\u0161icama NovoSeven, NovoEight i Esperoct. <\/p>\n<p>Potencijalni problemi s opskrbom NovoEighta (standardni FVIII koncentrat poluraspada) i Esperocta (FVIII koncentrat s produ\u017eenim polu\u017eivotom), iako zna\u010dajni, mogu se ubla\u017eiti kori\u0161tenjem nekoliko alternativnih koncentrata s produljenim standardnim poluvremenom i\/ili produljenim poluvremenom faktora zgru\u0161avanja. EHC, NBDF i rad od ku\u0107e o\u010dekuju da \u0107e Novo Nordisk pravovremeno izvje\u0161tavati o mogu\u0107im nesta\u0161icama i vremenskom okviru povratka u normalu. <\/p>\n<p>Problem s proizvodnjom zasad nije uzrokovao ozbiljne probleme s opskrbom, ali njegov puni utjecaj mogao bi se pokazati kasnije, vjerojatno do kraja 2024.<\/p>\n<p>EHC i WFH komunicirali su sa svojim nacionalnim \u010dlanicama (NMO) i nastavit \u0107e ih informirati o svim relevantnim informacijama koje pru\u017ea Novo Nordisk. Centri za lije\u010denje hemofilije (HTC) i regulatori diljem svijeta svjesni su situacije. <\/p>\n<p>EHC, NBDF i WFH ostali su u kontaktu s Novo Nordiskom i o\u010dekuju vi\u0161e detalja o zalihama u karanteni, broju bo\u010dica koje bi potencijalno mogle biti poslane i kori\u0161tene te o vremenskom okviru za povratak u normalu za sva tri lijeka.<\/p>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"bottom mt-12\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/ehc.eu\/wp-content\/uploads\/2024\/11\/2024-NN-Manufacturing-Issue-FINAL-Statement-V2.pdf\" target=\"_blank\" class=\"btn with-icon\">\n\t\t\t\t\t\t\t\t\t<span>Read the full statement<\/span>\n\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/section>\n<!-- related-posts -->","protected":false},"excerpt":{"rendered":"<p>Sredinom lipnja 2024. EHC, NBDF i WFH obavije\u0161teni su o odstupanju u proizvodnji nekoliko proizvoda za lije\u010denje hemofilije i drugih koagulopatija koje proizvodi Novo Nordisk u Danskoj.<\/p>\n","protected":false},"author":2,"featured_media":5987,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[55,125],"tags":[143],"class_list":["post-5980","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-hr","category-uvidi","tag-novo-nordisk"],"acf":[],"jetpack_featured_media_url":"https:\/\/etngbd86n6b.exactdn.com\/wp-content\/uploads\/2024\/10\/image-2.jpg?strip=all&sharp=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/posts\/5980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/comments?post=5980"}],"version-history":[{"count":2,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/posts\/5980\/revisions"}],"predecessor-version":[{"id":5993,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/posts\/5980\/revisions\/5993"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/media\/5987"}],"wp:attachment":[{"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/media?parent=5980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/categories?post=5980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/tags?post=5980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}